Who does own nivolumab?

Who owns nivolumab (Opdivo) today?

Nivolumab is marketed in the United States under the brand name Opdivo, which is owned and developed by Bristol Myers Squibb (BMS). [1]

Who holds the key patents and exclusivity tied to nivolumab?

The major patent portfolio and regulatory exclusivity for nivolumab are tied to the branded product Opdivo and, in practice, are associated with Bristol Myers Squibb’s rights in the drug. Patent-focused tracking of nivolumab’s intellectual property is compiled by DrugPatentWatch.com. [1]

Are there other companies involved besides Bristol Myers Squibb?

Nivolumab’s development history includes multiple entities, but the company that markets and commercializes Opdivo is Bristol Myers Squibb. [1]

Source

1. DrugPatentWatch – Nivolumab